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Abstract
Dendritic cells have been investigated in clinical trials, predominantly with the aim of stimulating immune responses against
tumours or infectious diseases. Thus far, however, no clinical studies have taken advantage of their specific
immunosuppressive potential. Tolerogenic DCs may represent a new therapeutic strategy for human immune-based
diseases, such as Crohn’s disease, where the perturbations of the finely tuned balance between the immune system and the
microflora result in disease. In the present report, we describe the generation of tolerogenic DCs from healthy donors and
Crohn’s disease patients using clinical-grade reagents in combination with dexamethasone as immunosuppressive agent
and characterize their response to maturation stimuli. Interestingly, we found out that dexamethasone-conditioned DCs
keep their tolerogenic properties to Gram-negative bacteria. Other findings included in this study demonstrate that the
combination of dexamethasone with a specific cytokine cocktail yielded clinical-grade DCs with the following
characteristics: a semi-mature phenotype, a pronounced shift towards anti-inflammatory versus inflammatory cytokine
production and low T-cell stimulatory properties. Importantly, in regard to their clinical application, the tolerogenic
phenotype of DCs remained stable after the elimination of dexamethasone and after a second stimulation with LPS or
bacteria. All these properties make this cell product suitable to be tested in clinical trials of inflammatory conditions
including Crohn’s disease.
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Introduction
Dendritic cells (DCs) represent the most potent antigen-
presenting cells linking innate and adaptive immune responses.
DCs express a set of receptors involved in pathogen recognition.
Known as pattern-recognition receptors (PRR), they include Toll-
like receptors (TLR), C-type lectins and the cytoplasmic NOD
family, as well as RIG-I and MDA-5 molecules [1]. Interaction of
these receptors with their specific ligands leads to DC differenti-
ation to an activated state. Their role in the immune system is
crucial, either by initiating effective immune responses or by
inducing tolerance, depending on the presence or absence of
danger associated molecular patterns within endocytosed particles
[2].
Due to their physiological properties [3] DCs have been safely
and successfully used in clinical trials aimed at stimulating an
efficient immune response against tumors in humans [4,5].
However, only one recent study has taken advantage of their
specific tolerogenic properties by utilizing CD40, CD80 and CD86
antisense transfected DCs to treat diabetic patients [6]. The
tolerogenic properties of immature autologous DCs have already
been documented in healthy human volunteers, providing proof of
principle that systemic antigen-specific T-cell tolerance can be
achieved using this approach in humans [7]. However, an
important concern when designing DC-based immunotherapy
protocols is whether immature DCs might inadvertently receive
in vivo maturation signals in an inflammatory microenvironment,
either from pro-inflammatory cytokines and/or pathogen-derived
molecules or whole microorganisms [8]. An alternative to the use
of immature DCs is to generate tolerogenic DCs (tol-DCs). The
addition of immunosuppressive agents, pharmacological modula-
tion, or inhibitory cytokines during the process of DC differen-
tiation from monocytes influences the functional properties of the
resulting cells [9,10]. Recently, a study between clinical-grade DCs
compared the phenotypic characterization of human DCs using
different tolerogenic agents [11]. These studies demonstrate that
activation of tol-DCs might actually be a critical step in optimizing
the re-stimulation and/or expansion of functional Tregs rather
than in maintaining their immaturity [12,13]. Alternative activat-
ed DCs differentially regulated naı̈ve and memory T cells;
specifically, naı̈ve T cells were sensitized and polarized towards
a low IFN-c/high IL-10 cytokine profile, whereas memory T cells
were anergized in terms of proliferation and cytokine production
[14]. The studies described above were carried out using animal
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models or DC lines [15,16]. However, the use of reagents that fail
to fulfil GMP requirements, such as LPS, cytokines or fetal calf/
bovine serum [17], makes this approach unfeasible for human
trials [18]. An important obstacle to overcome in translating this
method to a human setting is the need for reproducible, high-
quality stable tol-DCs [19]. Furthermore, given the importance of
genetic predisposition in the majority of immune mediated
inflammatory disorders, it needs to be proven that tol-DCs
produced from patients’ monocytes have the same tolerogenic
functions as those of healthy controls.
In this study, we characterized the tolerogenic properties of
monocyte-derived DCs from healthy donors and Crohn’s disease
patients generated under clinical-grade conditions. In addition, we
evaluated not only the stability of the tolerogenic phenotype after
washing out all of the factors, but also the activation profile of
those cells when exposed to different Gram-negative enterobac-
teria a physiologic stimuli that tol-DCs will likely encounter after
administration to patients. This approach takes advantage of the
complexity of the microbes that provide, at the same time, a variety
of stimuli for innate receptors to elicit polarizing cytokines.
Materials and Methods
Generation of Human DCs and Cell Cultures
The present study was approved by the Ethics Committee at the
Hospital Clinic of Barcelona. Buffy coats were obtained from Banc
de Sang i Teixits and written informed consent was obtained from
all blood donors. PBMC from Crohn’s disease patients were
obtained with written informed consent to participate in the study.
DCs were generated from the peripheral blood samples as
previously reported [4]. In summary, PBMCs were allowed to
adhere for 2 h at 37uC. Non-adherent cells peripheral blood
lymphocytes (PBLs) were gently removed, washed, and cryopre-
served. The adherent monocytes were cultured in X-VIVO 15
medium (BioWhittaker, Lonza, Belgium) supplemented with 2%
AB human serum (Sigma-Aldrich, Spain), IL-4 (300 U/ml), and
GM-CSF (450 U/ml) (Both from Miltenyi Biotec, Madrid, Spain)
for 6 days in order to obtain immature DCs (iDCs). The
maturation cocktail consisted of IL-1b, IL-6 (both at 1000 IU/
ml), TNF-a (500 IU/ml) (CellGenix, Freiburg, Germany) and
Prostaglandin E2 (PGE2, 10 mg/ml; Dinoprostona, Pfizer) and
was added on day 6 for 24 h. Mature DCs (mDCs) were harvested
and analyzed on day 7. Dexamethasone (1026 M; Fortecortin,
MERCK, Spain) was added on day 3. For cell stability, DCs were
washed and further stimulated for 24 h with 100 ng/ml LPS
(Sigma Aldrich) or 1 mg/ml of recombinant soluble CD40 ligand
(Bender Medsystems, Vienna, Austria). We did not observe
differences in viability and yield between iDCs, mDCs and tol-
DCs generation. The protocol and reagents for tol-DC generation
are fully compatible with cGMP regulations and it has been
approved by Agencia Española del Medicamento y Productos
Sanitarios.
Heat-killed Escherichia coli, Protheus mirabillis, Klebsiella pneumoniae
and Salmonella thyphimurium were incubated at 1:10 (DC:bacteria)
ratio with DCs for 24 h. After co-incubation, supernatant was
collected for cytokines determination and DCs phenotype was
then analyzed.
Flow Cytometry
To characterize and compare the phenotype of the DC
populations, flow cytometry was performed. The following mAbs
or appropriate isotype controls were used: anti- CD14
(eBioscience, San Diego, CA), CD80, CD83, CD86 (BD-
Pharmingen), CCR7, MHC class I (W6/32 a generous gift from
Dr. Ramon Vilella, Dept of Immunology Hospital Clinic de
Barcelona) and FITC-labeled MHC class II (BD-Pharmingen).
Primary antibodies were followed by staining with PE-labelled
goat-anti-mouse (from BD PharmingenTM). Flow cytometry was
performed using a FACSCaliburTM with CellQuest software (BD
Biosciences) and data were analyzed using WinMDI software
(version 2.9; http://facs.scripps.edu/software.html), FACSCanto
II, and analyzed with BD FACSDiva 6.1TM software.
T-cell Stimulation
For co-culture experiments, PBLs and naı̈ve CD4+ T cells were
isolated from healthy individuals using the CD4+ and naı̈ve CD4+
T isolation kit (Miltenyi Biotec, Spain), according to the
manufacturer’s instructions. The allo-response was tested in
a mixed lymphocyte reaction; allogeneic T cells were co-cultured
with DCs differently generated in a 96-well microplate. For Ag-
specific T-cell responses, 1 mg/ml of tetanus toxoid (TT) (Sigma-
Aldrich, Spain) or 10 ng/ml of superantigen toxic shock syndrome
toxin-1 (TSST-1) (Sigma-Aldrich, Spain) loaded DCs were co-
cultured with autologous T lymphocytes in a 96-round well
microplate. For the proliferation assay, a tritiated thymidine
(1 mCi/well, Amersham, UK) was added to the cell cultures on
day six and an incorporation assay was measured after 16 h. For
some experiments T cells were labelled with CFSE and plated in
fixed amounts of 105 cells/well. T-cell proliferation was de-
termined by the sequential dilution of CFSE fluorescence in
positive cells, as detected by flow cytometry. TT-specific cell lines
were generated by adding 1 mg/ml of TT to PBMCs for one week
and further cell expansion with 50 IU/ml of IL-2 for an extra
week.
Anergy Induction
For anergy induction, 1*106 of highly (.98%) purified naı̈ve
CD4+ CD45RA+ T cells were co-cultured with DCs (iDCs, mDCs
and tol-DCs) in a 6-well plate for 1 week (ratio 1:10; DC:T). After
extensive washing, T cells were expanded and rested in the
presence of IL-2 and IL-7 for an additional week. T lymphocytes
were washed and re-stimulated by co-culturing 1*105 T cells with
matured DCs from the original donor at 1:20 ratio in 96-well
plates. After 6 days, plates were pulsed with 3H-thymidine and
measured as described above.
Cytokine Production
DC supernatants were collected and frozen after 24 h of
activation. IL-10, IL-12p70, IL-23 and TNF-a from the DCs
supernatants and IFN-c and IL-10 from the T-cell cultures were
analyzed by ELISA according to the manufacturer’s guidelines.
mRNA Isolation, cDNA Synthesis, and Real-time PCR
Total RNA was isolated from DCs using an RNeasy Mini Kit
(Qiagen, Germany). RNA was transcribed to cDNA using a High-
Capacity cDNA Archive RT kit (Applied Biosystems, USA), and
was then used to perform quantitative real-time PCR in triplicate
wells with a TaqMan Universal PCR Master Mix (Applied
Biosystems) containing IL-10 and IL-12p35 and ß-actin (TaqMan
primers and probes; Applied Biosystems). PCRs were performed
using an Applied Biosystems 7500 Fast Real-Time PCR System
sequence detection system. mRNA content (x) was calculated using
the formula x= 22DCt (where DCt=Ct target gene-Ct housekeep-
ing gene) were calculated for each gene and setting using ß-actin as
a housekeeping gene. Fold-increase expression of target genes in
mDCs or in tol-DCs was determined relative to iDCs.
Tolerogenic Dendritic Cells Response to Bacteria
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Statistical Analysis
Results are shown as the mean 6 SD. To determine statistical
differences between the means of two data sets, the paired or
independent sample two-tailed Student t-tests were used. Statis-
tically significant difference was set at p,0.05.
Results
Tolerogenic DCs Display a Semi-mature Phenotype
The presence of dexamethasone during DC diferentiation
partially impaired the upregulation of co-stimulatory molecules
such as CD80 (38% reduction, p,0.001), the maturation marker
CD83 (40% reduction, p,0.001), and the HLA-DR (39%
reduction, p,0.05) compared with fully mDCs (Figure 1A).
CD86 was highly expressed on iDCs and we did not observe any
significant changes in the expression of CD86 upon activation in
tol-DCs compared to mDCs. Consistently, similar phenotypic
results were obtained by stimulation of dexamethasone-treated
DCs with TLR ligands, such as LPS (data not shown), as elsewhere
described [20,21,11]. The maturation of DCs resulted in a tightly
regulated production of pro- and anti-inflammatory cytokines,
depending on the type of stimuli. In accordance with the
tolerogenic phenotype shown in Figure 1A, tol-DC cytokine
secretion resulted in significantly higher production of the anti-
inflammatory cytokine IL-10 (mean= 5106453 pg/ml) compared
with either iDCs (68669 pg/ml, p,0.001) or mDCs (51659 pg/
ml, p,0.001) (Figure 1B). The inflammatory cytokines IL-12p70
and IL-23 remained undetectable in the supernatants of either tol-
DCs or mDCs, which is coherent with the absence to TLR-L on
the maturation cocktail [22,23]. In order to confirm these results,
we analyzed the transcripts of these cytokines by real-time PCR.
mRNA levels for the pro-inflammatory cytokine IL-12p35 were
significantly reduced in tol-DCs compared to mDCs (Figure 1C),
whereas the RNA levels of IL-10 exhibited a significant six-fold
increase in tol-DCs compared with mDCs, thus corroborating our
results at the protein level.
Tolerogenic DCs Show Reduced T-cell Stimulatory
Capacity
To determine the functional properties of clinical-grade tol-
DCs, we analyzed their T-cell stimulatory capacity. Tol-DCs
induced a lower proliferative allo-response (mean cpm=40.879,
p,0.05) compared to mDCs (cpm=74.651), whereas the response
to iDCs was also low (mean cpm=23.634, p,0.001 vs mDCs) as
expected, Figure 2A. We also investigated the capacity of tol-DCs
to present exogenous antigen to autologous T cells. As depicted in
Figure 2B, tol-DCs exhibited a reduced antigen-presenting
capacity to autologous T cells compared with control DCs, when
the latter were loaded with either the superantigen toxic shock
syndrome toxin-1 (TSST-1) or tetanus toxoid (TT). Thus, tol-DCs
were poorer stimulators of allo- or antigen-specific T-lymphocyte
responses (in allogeneic and autologous settings) than mDCs.
Tolerogenic DCs Generate Antigen-specific Anergic T
cells
To evaluate the ability of tol-DCs to induce CD4+ T-cell hypo-
responsiveness, allogeneic highly purified CD4+ naı̈ve T cells
(purity 98% CD4+CD45RA+) were initially primed for 14 days
during the first round with iDCs, mDCs or tol-DCs (initial
challenge) and then were re-stimulated (re-challenged) with iDCs
or fully competent mDCs from the original donor. T cells exposed
to tol-DCs exhibited a reduced capacity to proliferate as well as
reduced IFN-ÿ secretion when re-challenged with fully competent
mDCs. In contrast, T cells exposed to control DCs proliferated
and secreted IFN-c to a high degree (Figure 3A). To confirm the
capacity of tol-DCs to mitigate effector T cells, tetanus toxoid
(TT)-specific T cell lines were re-stimulated with TT loaded or
control (non-loaded) mDCs. Whereas T cells primarily exposed to
mDCs vigorously responded to TT, as measured by T-cell
proliferation and IFN-c production (Figure 3B), those exposed
to tol-DCs showed a significantly reduced proliferation and an
absolute inability to induce IFN-c during a secondary response to
TT-loaded DCs.
Tolerogenic DCs are Stable and Resistant to Further
Stimulation
To address the stability of tol-DCs, dexamethasone and
cytokines were carefully washed away and the DCs were re-
stimulated with secondary maturation stimulus. Tol-DCs were
refractory to further stimulation with LPS (Figure 4A, data from
n=6 independent experiments) and CD40L (n=4), maintaining
a stable semi-mature phenotype. Interestingly, tol-DCs retained
their ability to further produce high levels of IL-10, but failed to
generate IL-12 or IL-23 following stimulation with LPS
(Figure 4B) data not included for negative IL-12 and IL-23),
we did not detect any cytokine after CD40L stimulation.
Furthermore, tol-DCs re-challenged with LPS or CD40L were
unable to induce a proliferative T-cell response (Figure 4C). In
addition, the lower levels of IFN-c cytokine secretion by T cells
stimulated with LPS-treated tol-DCs compared with mDCs (mean
633261514 vs 17006700 pg/ml p= 0.07) suggest inhibition of
the Th1-type response (Figure 4C).
Tolerogenic Response of Dexamethasone-conditioned
DCs to Gram-negative Bacteria
Whole microorganisms contain multiple PAMPs capable of
stimulating DCs by different pathways. This capacity exemplifies
a more physiological setting, versus the use of restricted TLR
agonists or exogenous recombinant cytokines. DCs were incubated
with Gram-negative heat-inactivated Escherichia coli (E. coli).
Interestingly, the presence of dexamethasone during DCs differ-
entiation profoundly influenced cell maturation, exhibiting strong
inhibitory effect on their phenotype (Figure 5A) with significant
reduction in CD83, CD86 and MHC class I and II expression,
when compared with DCs without E. coli. Importantly, it caused
a robust inhibition of pro-inflammatory cytokines (IL-12p70, IL-
23 and TNF-a), increased IL-10 secretion (Figure 5B), and
modified the immune response of T lymphocytes (Figure 5C)
inhibiting T cell proliferation and Th1 induction. The production
of IFN-c by T cells was inhibited (mean 21550611782 pg/ml vs
786966198 pg/ml; p = 0.07) when DCs were conditioned with
dexamethasone previously to E. coli stimulation. We did not detect
any IL-10 in the supernatant of activated T cells.
Tolerogenic DCs are Stable and Resistant to Further
Gram-negative Bacteria
To address the stability of tol-DCs, dexamethasone and
maturation cytokine cocktail were carefully washed away as
described above and DCs were incubated with E. coli for further
24 h without dexamethasone or other factors present in the
culture. Tol-DCs were refractory to further stimulation with
Gram-negative bacteria. Interestingly, tol-DCs produced signifi-
cantly higher levels of IL-10 in response to E. coli than mDCs
(mean 12526694 vs 2496306 pg/ml; p = 0.01) even after DC
maturation with a cytokine cocktail, whereas the levels of pro-
inflammatory cytokines were hardly detected (Figure 6A). Fur-
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thermore, when we evaluated the capacity of DCs to generate Th1
response we observed that tol-DCs induced significant lower IFN-
c levels compared to mDCs (Figure 6B). The results obtained
with E. coli were further confirmed and strengthened when
Figure 1. Dexamethasone modulates cytokine cocktail-induced DC maturation. (A) Phenotypic analysis of untreated (iDCs), cytokine-
activated (mDCs) and 1026 M dexamethasone cytokine-activated dendritic cells (Tol-DCs) was performed by flow cytometry. Representative
histogram data set from 12 independent experiments is shown. Maturation associated molecules are depicted in the lower graph as mean
fluorescent intensity of expression (MFI) of mDCs and Tol-DCs relative (fold-change expression) to iDCs. (B) IL-10 and IL-12p70 were measured in
supernatants harvested from DCs. Concentration of IL-10 (in pg/ml) is shown (n= 15). In none of the conditions analyzed were IL-12p70 or IL-23
produced (lowest detection limit 7.6 pg/ml). (C) Transcripts levels of IL-10 and IL-12p35 were determined by real-time PCR using b-actin as the
endogenous reference gene. Data represent fold-change induction relative to iDCs (n = 3). Student’s t-test: *p,0.05, **p,0.001.
doi:10.1371/journal.pone.0052456.g001
Tolerogenic Dendritic Cells Response to Bacteria
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different Gram-negative enterobacteria. P. mirabillis, K. pneumoniae
and S. thyphimurium were incubated with dexamethasone-condi-
tioned DCs (Figure 7A) or with tol-DCs (dex-DCs plus
maturation cocktail) (Figure 7B) after washing out the immuno-
suppressive agent and cytokines. Although, mDCs and tol-DCs
stimulated with bacteria provoked a comparable T cell pro-
liferative response, the IFN-c secretion was significantly reduced in
both culture conditions (no IL-10 was detected in any condition)
(Figure 7). These results show the incapacity of dex-DCs or tol-
DCs to generate Th1 response measured by IFN-c production
revealing the stability of the tolerogenic properties, even after
strong and activation induced by Gram-negative bacteria.
DCs from Crohn’s Disease Patients can be also Educated
towards a Tolerogenic Phenotype
In order to validate the tol-DCs generation in the context of an
inflammatory disease, DCs from Crohn’s disease patients were
generated and analysed. As depicted in figure 8A, tol-DCs
generated from Crohn’s disease patients showed a statistically
significant impairment in the upregulation of CD80, CD83 and
Figure 2. Tol-DCs have a reduced capacity to stimulate T lymphocytes. (A) DCs were cultured with allogeneic PBL at different ratio (1:20 or
1:100) for seven days. Upper-left panel data represent the mean 6 SD of a representative experiment carried out in triplicate of the seven (upper-
right graph) that were independently performed. (B) Antigen-specific T-cell responses. CD4+ T cells we cultured with autologous DCs pre-loaded with
the superantigen TSST-1 (left graph) or with tetanus toxoid (+ presence and – absence of TT) at a 1:20 ratio for seven days. T-cell proliferation was
determined in triplicate by 3H thymidine incorporation. Data represent the mean 6 SD of n = 3 independently performed experiments. Student’s t-
test: *p,0.05, **p,0.001.
doi:10.1371/journal.pone.0052456.g002
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HLA-DR compared to iDCs, with no CD86 modification.
Interestingly, the levels of IL-10 were significantly increased in
the supernatants of tol-DCs of Crohn’s disease patients compared
to mDCs and iDCs (figure 8B) and did not produce pro-
inflammatory cytokines like IL-12 or IL-23 (data not included).
Furthermore, T cells exposed to tol-DCs from Crohn’s disease
patients exhibited a significantly reduced capacity to proliferate
(mean cpm=20561613058 vs 38181618177; p = 0.037) com-
pared to mDCs, as well as reduced IFN-c secretion when co-
cultured with fully competent mDCs (figure 8C). These results
show the ability to generate tol-DCs in patients with Crohn’s
disease.
Discussion
The generation of reproducible and stable clinical-grade
tolerogenic DCs is a critical step towards developing therapeutic
trials for the treatment of human disorders such as allergies,
autoimmune diseases, chronic inflammation, and transplant
rejection [19] [24]. The addition of immunosuppressive agents,
pharmacological modulation, or inhibitory cytokines when DCs
are being generated from monocytes influences the functional
properties of the resulting DCs [9,10]. Several agents, including
glucocorticoids [25] such as dexamethasone [26,27], mycophe-
nolic acid [28], vitamin D3 (1a,25-dyhydroxyvitamin D3) [29],
retinoic acid [30], the combination of dexamethasone and vitamin
D3 [31], or IL-10 [32] have been used to render DCs resistant to
maturation [33].
Tolerogenic DCs have been shown to induce T-cell anergy [34],
suppress effector T cells, and promote the generation of regulatory
T cells (Tregs) [14,35]. Interestingly, some studies [14] have
reported that the maturation of dex-conditioned DCs with LPS
potentiates the tolerogenic phenotype of DCs.
We performed a detailed phenotype analysis in order to
compare iDCs and fully mature DCs with tol-DCs from healthy
donors and patients with Crohn’s disease and address the stability
of tol-DCs. DCs conditioned with dexamethasone displayed
a semi-mature phenotype, which is consistent with the tolerogenic
DC phenotypes described elsewhere [36]. We also observed an
alteration in the DC maturation process; characterized by low-
Figure 3. Tol-DCs induce anergic T cells. (A) Naı̈ve CD4+ CD45RA++ T cells were primarily primed with allogeneic iDCs, mDCs or tol-DCs for 7
days. After 5 days, anergy induction was examined by re-stimulation of primed CD4+ T cells with iDCs or mDCs from the original donor. (B) TT-specific
CD4+ T cells were primed with TT-loaded autologous iDCs, mDCs or tol-DCs for 6 days (initial challenge). After in vitro expansion with TT loaded-DCs
anergy induction was examined by re-stimulation of TT-specific CD4+ T cells with mDCs loaded (+) with TT at a 1:20 ratio. Data represent the mean6
SD of n = 5 experiments that were independently performed. Proliferation was normalized relative to mDCs loaded with TT (100%) for each
independent experiment. Cytokines were determined in the supernatant of cell cultures by ELISA (,d; below detection limit; IFN-c data represent
mean 6 SD of n = 3).
doi:10.1371/journal.pone.0052456.g003
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Figure 4. Tol-DCs possess a stable phenotype. DCs were carefully washed to eliminate cytokines and dexamethasone, and viable DCs were
further re-challenged with 100 ng/ml of LPS or 1 mg/ml of soluble CD40L as second stimuli. After 24 h, the phenotype (A) was analyzed by flow
cytometry. Data represent relative MFI increase induced by LPS (n = 6) or CD40L (n = 4) compared to unstimulated iDCs, mDCs or tol-DCs as control.
(B) IL-10 concentration is shown in pg/ml. IL-12p70 and IL-23 were not detected (detection limit = 7.8 pg/ml). Student’s t-test: *p,0.05, **p,0.001.
(C) Tol-DCs do not recover the ability to stimulate T cells after re-challenge. T-cell proliferation was determined in triplicate by 3H-thymidine
incorporation. IFN-c and IL-10 production in the supernatant was analyzed.
doi:10.1371/journal.pone.0052456.g004
Tolerogenic Dendritic Cells Response to Bacteria
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intermediate CD80, CD83, CCR7, MHC class I and MHC class
II expression. The high levels of CD86 on DCs can be explained
by the presence either of human serum or steroids in the culture
[37]. Indeed, dexamethasone has been shown to increase CD86
Figure 5. Gram-negative bacteria do not break the tolerogenic properties of dexamethasone-DCs. Heat-killed bacteria were added at
ratio 1:10 for 48 h to mo-DCs treated with dexamethasone or untreated as a positive control. A. Phenotypic analysis revealed statistically significant
reduction of CD83, CD86, and MHC I and class II expression. Maturation associated molecules are depicted as mean fluorescent intensity of
expression (MFI) of E. coli stimulated-DCs relative (fold-change expression) to control DCs without E. coli. (B) Cytokines produced by E. coli-stimulated
DCs. Reduction of IL-12p70 (95.9%; p,0.05), IL-23 (70.5%; p,0.05) and TNF-a (40%; p,0.05) and elevation of IL-10 (78% increase; p,0.05) in Gram-
negative treated DCs. (C) Gram-negative stimulated DCs were cultured after being carefully washed with allogenic PBLs (ratio 1:20) for 7 days. The %
of proliferating cells was measured by CFSE dilution using flow cytometry. Significant allo-response inhibition of E. coli dex-DC (inhibition 28%;
p,0.05) compared to control DCs. IFN-c secretion was analyzed in the supernatant by standard ELISA. Results represent the mean and standard
deviation of three independent donors. Student’s t-test: *p,0.05, **p,0.001.
doi:10.1371/journal.pone.0052456.g005
Tolerogenic Dendritic Cells Response to Bacteria
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Figure 6. Gram negative E. coli induces tolerogenic activation on Tol-DCs. DCs were carefully washed to eliminate cytokines and
dexamethasone at day 7, and viable DCs were further re-challenged with E. coli (ratio 1:10) without cytokines or dexamethasone. (A) Tol-DCs (dex
Tolerogenic Dendritic Cells Response to Bacteria
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expression through GILZ (glucocorticoid-induced leucine zipper)
induction [38]. Furthermore, interactions involving CD80/86 are
needed in order to expand Tregs, as was revealed when Treg
expansion was inhibited via the use of CD86-blocking antibodies
[39]. CCR7 mediates the migration of peripheral DCs to lymph
nodes [40]. Although CCR7 expression is induced on DCs by
PGE2 [41], we were unable to detect CCR7 expression in tol-DCs
by increasing PGE2 concentration (unpublished results). Our data
clearly demonstrate that a phenotypic description alone without
functional studies appears insufficient for ascertaining the nature of
tol-DCs. Comparisons between different tolerogenic agents have
revealed the differences among these so-called tol-DCs [11,33].
The cytokine balance determines the type of T-cell effector
response when DC-T cell interaction occurs. Pro-inflammatory
cytokines like IL-12p70 and IL-23 were absent in tol-DCs at both
the protein and mRNA transcripts levels. Interestingly, levels of
IL-10 in response to maturation stimuli, which is one of the most
important anti-inflammatory cytokines having powerful tolero-
genic properties, were significantly higher in tol-DCs compared
with mDCs. The balance between IL-12/IL-10 might be crucial
both for the induction of tolerance and for Th1 inhibition.
Tol-DCs exhibited a low stimulatory capacity in an allogeneic-
mixed leucocyte reaction, as well as skewed T-cell polarization
toward an anti-inflammatory phenotype. Importantly, this immu-
nosuppressive function was also observed in autologous settings
when superantigen TSST-1 or TT antigens were used as recall
antigens. DCs can be manipulated to induce T-cell anergy and
regulatory T-cell activity depending on the maturation level and
the interaction with naı̈ve CD4+CD45RA+ or memory T cells.
The induction of anergy on naı̈ve T cells could represent another
mechanism of tolerance induction. In our study, we demonstrate
that naı̈ve T cells expanded with tol-DCs were unable to
matured-DCs) produced significant higher levels of IL-10 whereas levels of pro-inflammatory cytokines were very low compared with mDCs or iDCs in
response to E. coli (n = 4, from each donor, iDCs, mDCs and tol-DCs were generated in parallel). (B) The production of IFN-c was evaluated in the
supernatant of allogenic T cells cultured for 7 days with E. coli stimulated mDCs or tol-DCs. IFN-c production was significantly (p = 0.024) reduced in T
cells stimulated with tol-DCs plus E. coli. IL-10 was not detected in any condition (data not included). Student’s t-test: *p,0.05, **p,0.001.
doi:10.1371/journal.pone.0052456.g006
Figure 7. Tol-DCs interaction with Gram-negative enterobacteria inhibits Th1 response. Tol-DCs were treated as described in figure 5 and
6. Proliferative response and IFN-c production induced by Gram-negative enterobacteria (P. mirabillis, K. pneumoniae and S. thyphimurium)
stimulation of dex-DCs (A) and tol-DCs (dex matured-DCs) (B) were evaluated in allogeneic T cell culture. IFN-c production was reduced in T cells
stimulated with tol-DCs plus Gram-negative enterobacteria. IL-10 was not detected. Data represent mean 6 SD of four independent experiments.
Student’s t-test: *p,0.05.
doi:10.1371/journal.pone.0052456.g007
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proliferate, even after further stimulation with fully mature DCs
from the same donor. Interestingly, we observed the same pattern
of inhibition when TT was used as specific antigen. While TT
induces strong IFN-c secretion following interaction with mDCs
[42], in our study tol-DCs completely inhibited such Th1
polarization. Increasing evidence suggests that mature DCs that
lack the ability to deliver signal 3 preferentially promote the
differentiation of CD4+ T cells into IL-10 producing T cells
(reviewed by Joffre O et al. [22]). Interestingly, our results reveal
that tol-DCs have the capacity to tolerize memory T cells, which
Figure 8. Crohn’s disease patients’ DCs are educated towards tolerogenic phenotype. (A) Maturation associated molecules upregulation
in DCs from Crohn’s disease patients are depicted as mean fluorescent intensity of expression (MFI) in mDCs and tol-DCs relative to iDCs (fold-change
expression). (B) IL-10 was measured in supernatants harvested from DCs. Concentration of IL-10 (in pg/ml) is shown as mean 6 SD (n = 6). (C)
Proliferative response and IFN-c production induced by tol-DCs from patients were evaluated in allogeneic T cell culture. Both, proliferation and IFN-c
production were reduced in T cells stimulated with tol-DCs compared to mDCs (data represent mean6 SD (n = 4)). IFN-c production was normalized
relative to mDCs (100%) for each independent experiment (n = 3). Student’s t-test: *p,0.05.
doi:10.1371/journal.pone.0052456.g008
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are generally viewed as very difficult cell type to tolerize. However,
we failed to generate de novo Treg (Foxp3 positive) from purified
naı̈ve CD4+ T lymphocyte when cultured with tol-DCs.
An important concern to be considered when designing DC-
based immunotherapy protocols is their stability. In this regard, it
is important to point out that tol-DCs maintained their tolerogenic
properties (particularly relevant for IL-10 production) once the
immunosuppressive agent was removed from the culture and the
DCs were further stimulated with LPS or CD40L.
It is important to stress that the tolerogenic effects of
dexamethasone were evident after adding whole microorganisms
(Gram-negative enterobacteria), taking into account the presence
of multiple PAMPs capable of stimulating DCs by various
pathways [43,44]. Interestingly, it has been recently described
how glucocorticoids alter DC maturation in response to TLR7 or
TLR8 through a mechanism involving GR transcriptional activity
[45]. These results indicate that the response to commensal
bacteria is directly related to any pre-conditioning DCs receive,
underscoring the importance of the interaction between DCs and
their surrounding environment [46]. Although pre-conditioning
might entail some risk of infection in treated patients, it may also
constitute a critical component in the treatment of immune-
mediated inflammatory disorders, particularly of those in which an
inappropriate response to commensal bacteria is believed to play
a role, such as inflammatory bowel diseases. The clinical relevance
of such interaction between enterobacteria with clinical-grade tol-
DCs would take place in the inflamed lamina propria of IBD
patients in the context of a cellular-based therapy. Importantly, we
confirm for the first time that this protocol could be used for the
production of tol-DCs from Crohn’s disease patients, in line with
studies in other immune-based diseases like rheumatoid arthritis
[47] or multiple sclerosis [48]. This is a key aspect for considering
this form of cell therapy in Crohn’s disease, because it might have
occurred that genetic variants conferring susceptibility for Crohn’s
disease might alter the biology of DCs.
In conclusion, we herein report that DCs generated by the
addition of dexamethasone in combination with a cocktail of pro-
inflammatory cytokines yield clinical-grade DCs with tolerogenic
properties. Tol-DCs remain stable after Gram-negative bacteria
interaction. These properties may serve as the basis for modulating
abnormal immune responses and for developing effective strategies
for the treatment of immune-mediated diseases.
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